切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 165 -171. doi: 10.3877/cma.j.issn.1674-1358.2022.03.004

论著

外周血单个核细胞内人类免疫缺陷病毒DNA和RNA定量对病毒转录活性的区分
杜娟1, 宋波2, 颜晓明3, 牛佳鸣4, 林元龙5, 陈晓红2, 李锦6, 梁晗7, 张铮8, 李宇欧9, 王福祥5, 邵冰3,()   
  1. 1. 132013 吉林市,吉林医药学院药学院
    2. 150001 哈尔滨市,哈尔滨医科大学附属第四医院感染科
    3. 132013 吉林市,吉林医药学院公共卫生学院
    4. 132013 吉林市,吉林医药学院临床医学部
    5. 518112 深圳市,深圳市第三人民医院感染三科
    6. 130123 长春市,长春市传染病医院艾滋病科
    7. 132002 吉林市,吉林市传染病医院感染科
    8. 361101 厦门市,厦门市第五医院感染科
    9. 150030 哈尔滨市,哈尔滨市第六医院感染科
  • 收稿日期:2021-09-18 出版日期:2022-06-15
  • 通信作者: 邵冰
  • 基金资助:
    国家自然科学基金(No. 81602899、81971915); 吉林省科技发展计划优秀青年人才基金项目(No. 20180520107JH); 吉林省卫生健康青年科技骨干培养计划(No. 2019Q034); 吉林省教育厅"十三五"科学技术项目(No. JJKH20200464KJ); 吉林省大学生创新创业训练计划项目(No. 201913706001)

Quantitative results of human immunodeficiency virus total deoxyribonucleic acid and ribonucleic acid in peripheral blood mononuclear cells to distinguish the activity of viral transcription

Juan Du1, bo Song2, Xiaoming Yan3, Jiaming Niu4, Yuanlong Lin5, Xiaohong Chen2, Jin Li6, Han Liang7, Zheng Zhang8, Yuou Li9, Fuxiang Wang5, Bing Shao3,()   

  1. 1. School of Pharmacy, Jilin Medical University, Jilin 132013, China
    2. Department of Infectious Diseases, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    3. School of Public Health, Jilin Medical University, Jilin 132013, China
    4. Clinical College, Jilin Medical University, Jilin 132013, China
    5. The Third Department of Infection, Shenzhen Third People’s Hospital, Shenzhen 518112, China
    6. Department of AIDS, Changchun Hospital Infectious Diseases, Changchun 130123, China
    7. Department of Infectious Diseases, Jilin Hospital of Infectious Diseases, Jilin 132002, China
    8. Department of Infectious Diseases, Xiamen Fifth Hospital, Xiamen 361101, China
    9. Department of Infectious Diseases, Harbin Sixth Hospital, Harbin 150030, China
  • Received:2021-09-18 Published:2022-06-15
  • Corresponding author: Bing Shao
引用本文:

杜娟, 宋波, 颜晓明, 牛佳鸣, 林元龙, 陈晓红, 李锦, 梁晗, 张铮, 李宇欧, 王福祥, 邵冰. 外周血单个核细胞内人类免疫缺陷病毒DNA和RNA定量对病毒转录活性的区分[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(03): 165-171.

Juan Du, bo Song, Xiaoming Yan, Jiaming Niu, Yuanlong Lin, Xiaohong Chen, Jin Li, Han Liang, Zheng Zhang, Yuou Li, Fuxiang Wang, Bing Shao. Quantitative results of human immunodeficiency virus total deoxyribonucleic acid and ribonucleic acid in peripheral blood mononuclear cells to distinguish the activity of viral transcription[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(03): 165-171.

目的

基于人类免疫缺陷病毒Ⅰ型(HIV-1)感染者外周血单个核细胞(PBMCs)中HIV-1总DNA和RNA定量检测结果对感染细胞内病毒的转录活性进行区分。

方法

采集2017年10月至2018年12月于哈尔滨医科大学附属第四医院感染科就诊的HIV-1感染者血液样本,分离PBMCs细胞,采用PCR荧光探针法对PBMCs细胞内HIV-1总DNA和RNA进行定量检测,并计算两者比值(Ratio)。根据Ratio值筛选出HIV-1转录活跃组样本和相对非活跃组样本,另外选择健康人PBMCs样本作为对照组。对3组样本进行基因转录组表达谱检测以及人口特征差异性检验,并对基因表达谱检测结果进行主成分分析以验证对3组样本病毒转录活性区分的准确性。

结果

从60例感染HIV-1患者的PBMCs样本中筛选出HIV-1转录活跃组样本(10例)和相对非活跃组样本(11例),另外选择6例健康人PBMCs样本作为对照组。其中转录活跃组样本Ratio值为165.2~738.93,平均为(339.27 ± 189.68);相对非活跃组Ratio值为4.67~42.39,平均为(17.65 ± 11.78)。转录活跃组和相对非活跃组样本间的CD4+ T细胞计数(P = 0.049)和Ratio值(P < 0.001)差异均具有统计学意义;3组样本年龄(P = 0.989)和性别(P = 0.650)分布差异无统计学意义。对3组样本的PBMCs基因表达谱主成分分析结果显示:对照组与HIV-1感染者(包括转录活跃组和相对非活跃组)间区分明显。转录活跃组和相对非活跃组间有部分样本重合,同时结果也显示当HIV-1感染者的CD4+ T淋巴细胞计数与健康人无显著差异时,其细胞内的基因表达与健康人接近。

结论

基于HIV-1总DNA和RNA定量检测结果及两者间比值可以较好地区分PBMCs内病毒转录活性。HIV-1感染细胞内部病毒的不同转录激活状况可导致其基因表达谱的异质性。

Objective

Based on the quantitative results of total deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) of human immunodeficiency virus type 1 (HIV-1) in peripheral blood mononuclear cells (PBMCs) of patients with HIV-1 infection, transcriptional activity of HIV was distinguished.

Methods

Blood samples and separate PBMCs from healthy persons and HIV-1 infectors were collected from October 2017 to December 2018 in the Department of Infectious Diseases, the Fourth Affiliated Hospital of Harbin Medical University, PCR fluorescent probe method was applied to detect quantitative total DNA and RNA of HIV-1 in PBMCs, and the ratio values between them were calculated. According to ratio values, HIV-1 active transcription group and relatively inactive group were screened. In addition, PBMCs samples from healthy people were selected as controls. Gene transcriptome expression profile detection and populational characteristics difference were performed among the three groups, and principal component analysis was performed on the gene expression profiles among the three groups to verify the accuracy of distinguishing intracellular viral transcriptional activity.

Results

The HIV-1 active group samples (10 cases) and the relatively inactive group samples (11 cases) were screened form PBMCs samples of 60 HIV-1 infectors, and the PBMCs samples from 6 healthy people were selected as control group. The ratio value in active transcription group was 165.2-738.93, the mean and standard deviation was (339.27 ± 189.68). In relatively inactive group, the ratio value was 4.67-42.39, the mean and standard deviation was (17.65 ± 11.78). There were statistically significant differences in CD4+ T counts (P = 0.049) and ratio values (P < 0.001) between the active transcription group and the relatively inactive group; there were no significant differences in age (P = 0.989) and gender (P = 0.650) distribution among the three groups. The principal component analysis results of gene expression profiles of PBMCs samples from the three groups showed that there was a clear difference between healthy people and HIV-1 infectors (active ranscription and relatively inactive groups), but some samples overlapped between the active ranscription group and the relatively inactive group. When CD4+ T lymphocyte count of HIV-1 infectors was the same as healthy people, the state of gene expression within infected cells is similar to that of healthy people.

Conclusions

The ratio value of quantitative detection results of total DNA and RNA of HIV-1 could better distinguish the intracellular viral transcriptional activity. Differently transcriptional activation status of virus in infected cells could lead to intracellular heterogeneity of gene expression profile.

表1 PBMCs细胞内HIV-1总DNA和RNA定量及样本转录活性的划分
样本号 年龄 性别 DNA*(拷贝/106 cell) RNA*(拷贝/106 cell) CD4+ T细胞(个/μl) Ratio值 分组
A1 38 1.18 × 103 8.73 × 102 608 738.83 活跃
A2 22 7.01 × 103 1.41 × 103 295 201.49 活跃
A3 30 8.41 × 103 4.70 × 103 94 559.40 活跃
A4 29 4.96 × 103 2.16 × 103 207 434.26 活跃
A5 27 1.05 × 103 1.74 × 102 463 165.20 活跃
A6 30 5.81 × 103 1.05 × 103 249 179.98 活跃
A7 28 3.29 × 103 8.45 × 102 353 256.59 活跃
A8 36 8.69 × 102 2.70 × 102 295 310.19 活跃
A9 25 8.12 × 102 1.50 × 102 328 184.92 活跃
A10 26 8.89 × 103 3.22 × 103 3 361.79 活跃
B1 47 5.48 × 102 1.69 × 101 350 30.83 相对非活跃
B2 38 3.96 × 102 6.08 × 100 612 15.35 相对非活跃
B3 25 6.61 × 102 1.19 × 101 371 18.00 相对非活跃
B4 22 1.80 × 102 7.61 × 100 278 42.39 相对非活跃
B5 36 6.42 × 102 7.15 × 101 648 11.14 相对非活跃
B6 31 3.98 × 103 1.86 × 101 579 4.67 相对非活跃
B7 23 4.55 × 103 4.42 × 101 323 9.70 相对非活跃
B8 29 6.38 × 103 5.82 × 101 205 9.12 相对非活跃
B9 27 1.99 × 103 1.11 × 101 354 5.56 相对非活跃
B10 24 6.11 × 103 1.21 × 101 1136 19.82 相对非活跃
B11 30 1.45 × 104 4.00 × 102 515 27.61 相对非活跃
C1 25 健康对照
C2 27 健康对照
C3 33 健康对照
C4 29 健康对照
C5 37 健康对照
C6 23 健康对照
图1 各组样本基因表达谱的主成分分析注:Blank:对照组,Case:活跃组,Control:相对非活跃组
[1]
Le T, Farrar J, Shikuma C. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication[J]. AIDS,2011,25(6):871-872.
[2]
吴润东,刘光明,庞伟. HIV潜伏感染激活剂研究进展[J]. 中国药理学通报,2014,30(1):1-6.
[3]
焦艳梅,吴昊. HIV-1潜伏库研究进展[J]. 首都医科大学学报,2009,30(5):639-642.
[4]
Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure[J]. AIDS,2012,26(10):1261-1268.
[5]
Julg B, Barouch DH. HIV-1 latency by transition[J]. Immunity,2017,47(4):611-612.
[6]
刘叔文,潘晓彦,赵伟. HIV治愈:潜伏HIV的清除及其策略[J]. 遵义医学院学报,2015,38(2):105-110.
[7]
于佩霞,刘兆鹏,李荀. HIV病毒潜伏库的形成机制和对策挑战[J]. 生命的化学,2021,41(1):97-105.
[8]
方敏,邓梅花,梁飞立. HIV感染抗逆转录病毒治疗时机的研究进展[J/CD]. 中华实验和临床感染病杂志(电子版),2016,10(2):136-139.
[9]
杜娟,颜晓明,牛佳鸣, 等. HIV-1感染者CD4+ T淋巴细胞数与外周血单个核细胞内病毒DNA和RNA定量检测结果的相关性[J]. 中国病毒病杂志,2021,11(5):347-350.
[10]
武佳伟,刘畅,梅庆步, 等. HIV-1感染与细胞周期调控的相关研究进展[J]. 国际遗传学杂志,2018,41(6):497-503.
[11]
Freed EO. HIV-1 assembly, release and maturation[J]. Nat Rev Microbiol,2015,13(8):484-96.
[12]
康文,汪春付,孙永涛. 实现HIV功能性治愈的策略和挑战[J]. 传染病信息,2014,27(6):328-332, 341.
[13]
Avettand-Fenoel V, Hocqueloux L, Ghosn J, et al. Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications[J]. Clin Microbiol Rev,2016,29(4):859-80.
[14]
陈霞,郑煜煌,加路, 等. 艾滋病抗病毒治疗中外周血细胞病毒库的动态变化及其意义[J]. 中南大学学报(医学版),2013,(5):537-544.
[15]
胡敏,朱碧帆,陆一涵, 等. CD4+ T淋巴细胞计数检测与HIV病毒载量检测在评价ART效果中的经济性比较及其影响因素[J]. 中国艾滋病性病,2016,22(4):232-236.
[16]
马媛媛,胡晓远,倪明健. 接受抗病毒治疗HIV/AIDS的CD4+ T淋巴细胞计数与病毒载量相关性评价[J]. 疾病预防控制通报,2019,34(6):18-20.
[17]
Pasternak AO, Lukashov VV, Berkhout B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence[J]. Retrovirology,2013,10:41.
[18]
赵准. 基于主成分分析的基因表达谱数据降维方法研究及可视化[D]. 2019: 哈尔滨工业大学.
[19]
王成雄,饶妮妮,王玉. 用主成分分析探索基因表达模式[J]. 生物医学工程学杂志,2007,24(4):736-741.
[20]
杨文万,石鸥燕,张菊芳. 主成分分析在基因表达谱数据分析中的应用[J]. 包头医学院学报,2005,21(4):435-436.
[21]
阿基业,何骏,孙润彬. 代谢组学数据处理--主成分分析十个要点问题[J]. 药学学报,2018,53(6):929-937.
[22]
王馨雨,王蓉蓉,王婷, 等.不同品种百合内外鳞片游离氨基酸组成的主成分分析及聚类分析[J]. 食品科学,2020,41(12):211-220.
[23]
吕婷霞,李太生. HIV相关免疫激活及炎症发生机制研究进展[J]. 中国艾滋病性病,2019,25(6):643-647.
[24]
Mousseau G, Valente ST. Role of host factors on the regulation of tat-mediated HIV-1 transcription[J]. Curr Pharm Des,2017,23(28):4079-4090.
[25]
Trypsteen W, Mohammadi P, Van Hecke C, et al. Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay[J]. Sci Rep,2016,6:36111.
[26]
Nair M, Sagar V, Pilakka-Kanthikeel S. Gene-expression reversal of lncRNAs and associated mRNAs expression in active vs latent HIV infection[J]. Sci Rep,2016,6:34862.
[27]
宁铁林,朱效科,郑敏娜. 天津地区健康人外周血CD4, CD8淋巴细胞正常参考值研究[J]. 中国慢性病预防与控制,2007,15(5):432-434.
[1] 吴茜, 邓力, 练士贤, 张华, 江颖, 张宏伟. 伴人类免疫缺陷病毒感染乳腺癌患者的临床病理特征与预后的相关性研究[J]. 中华乳腺病杂志(电子版), 2023, 17(03): 151-156.
[2] 张玉, 薛文瑞, 王鑫, 李旭瑜, 王旭东, 袁鹏飞, 梁雨润, 韩志兴, 张海建, 刘庆军, 纪世琪. 人类免疫缺陷病毒感染合并膀胱癌14例临床特点[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 354-358.
[3] 张小曼, 马筱秋, 许正锯, 张纯瑜, 何彩婷. 乙型肝炎病毒逆转录酶区耐药突变对血清乙型肝炎病毒表面抗原水平的影响[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 324-332.
[4] 崔贵香, 丁晓燕, 褚盈晖, 孙代, 吴海燕, 陈京龙. 57例人类免疫缺陷病毒感染合并Burkkit淋巴瘤患者的临床分析[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 102-109.
[5] 袁瑞, 胡文佳, 桂希恩, 严亚军, 冯玲, 柯亨宁, 熊勇, 杨蓉蓉. 淋巴细胞精细分型检测在人类免疫缺陷病毒感染者/获得性免疫缺陷综合征患者中的应用[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 84-91.
[6] 李倩, 邓莉平, 陈果, 张忠威, 莫平征, 胡文佳, 陈良君, 张捷, 张永喜, 杨蓉蓉, 熊勇. 宏基因组二代测序在获得性免疫缺陷综合征合并中枢神经系统感染中的临床应用[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 24-31.
[7] 于欣睿, 曾辉. Janus激酶-信号转导与转录激活因子信号通路与脓毒症关系的复杂性[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(06): 366-369.
[8] 汤艳芬, 赵雯, 马成杰, 刘刚, 陈奇, 刘菁, 薛天娇, 刘岩岩, 陈融佥, 王宇. 人类免疫缺陷病毒感染合并鸟分枝杆菌复合群病临床特点[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(05): 348-353.
[9] 魏春波, 万钢, 许东梅, 赵兴云, 袁柳凤, 吴焱, 伦文辉. 60例人类免疫缺陷病毒感染者/获得性免疫缺陷综合征合并神经梅毒患者临床和实验室特征[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(04): 254-260.
[10] 黄威, 刘启, 陈流华, 滕茶香, 区喆建, 刘韩笑, 陈健聪, 张昆松. 新定义的可预测肝癌预后的焦亡相关lncRNA模型[J]. 中华普通外科学文献(电子版), 2023, 17(05): 357-365.
[11] 张燕珍, 王锡携, 文小兰. 血清巨噬细胞迁移抑制因子对活动性肺结核分诊检测的意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 200-202.
[12] 张瑞琪, 张丽娟, 孙斌. 甲状腺相关性眼病表观遗传学的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 226-230.
[13] 王希岗, 张波, 李鸣, 高敏, 薛建新. 神经外科手术部位感染在HIV感染者与非HIV感染者中的临床差异[J]. 中华神经创伤外科电子杂志, 2023, 09(04): 228-233.
[14] 付强, 秦丽媛, 李全波. 神经病理性疼痛患者血清miR-15a水平及意义分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 293-298.
[15] 马强, 李军, 苟丽娟. 重症急性胰腺炎miR-21-3p、RUNX3表达水平及对病情发展程度的预测[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 337-341.
阅读次数
全文


摘要